# Anthera Pharmaceuticals clinical trials: 25 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 25 trials with Anthera Pharmaceuticals as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Anthera Pharmaceuticals: 25 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/anthera-pharmaceuticals

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 25
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 25, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| February 13, 2017 | NCT03051490 | RESULT: Reliable, Emergent Solution Using Liprotamase Treatment | Anthera Pharmaceuticals | Phase 3 | Unknown | Exocrine Pancreatic Insufficiency, Cystic Fibrosis | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03051490) |
| July 6, 2016 | NCT02823964 | EASY: Extended Access to Sollpura Over Years | Anthera Pharmaceuticals | Phase 4 | Completed | Exocrine Pancreatic Insufficiency, Cystic Fibrosis | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02823964) |
| April 12, 2016 | NCT02734810 | SIMPLICITY: Studying Impacts on Malabsorption With Liprotamase in Cystic Fibrosis | Anthera Pharmaceuticals | Phase 3 | Completed | Exocrine Pancreatic Insufficiency, Cystic Fibrosis | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02734810) |
| August 4, 2015 | NCT02514967 | CHABLIS7.5: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without... | Anthera Pharmaceuticals | Phase 3 | Terminated | Systemic Lupus Erythematosus | 3 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02514967) |
| October 31, 2014 | NCT02279498 | SOLUTION: Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in Patients With Cystic Fibrosis | Anthera Pharmaceuticals | Phase 3 | Completed | Exocrine Pancreatic Insufficiency, Cystic Fibrosis | 128 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02279498) |
| February 28, 2014 | NCT02074020 | CHABLIS-SC2: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without... | Anthera Pharmaceuticals | Phase 3 | Withdrawn | Systemic Lupus Erythematosus | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02074020) |
| February 14, 2014 | NCT02062684 | BRIGHT-SC: Blisibimod Response in IgA Nephropathy Following At-Home Treatment by Subcutaneous Administration | Anthera Pharmaceuticals | Phase 2/3 | Completed | IgA Nephropathy | 57 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02062684) |
| February 3, 2014 | NCT02052219 | BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy | Anthera Pharmaceuticals | Phase 3 | Withdrawn | IgA Nephropathy | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02052219) |
| June 1, 2012 | NCT01609452 | MONICA-SC: A Study to Evaluate the Efficacy, Safety and Tolerability of Blisibimod (A-623) Administration in Subjects With ITP | Anthera Pharmaceuticals | Phase 2/3 | Withdrawn | Immune Thrombocytopenic Purpura, Idiopathic Thrombocytopenic Purpura | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01609452) |
| May 15, 2012 | NCT01598857 | BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in... | Anthera Pharmaceuticals | Phase 2 | Withdrawn | Granulomatosis With Polyangiitis, Microscopic Polyangiitis | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01598857) |
| January 31, 2012 | NCT01522196 | A Study of Varespladib Infusion in Subjects With Sickle Cell Disease. | Anthera Pharmaceuticals | Phase 2 | Terminated | Sickle Cell Disease, Vaso-occlusive Crisis | 2 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01522196) |
| July 18, 2011 | NCT01395745 | CHABLIS-SC1: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus | Anthera Pharmaceuticals | Phase 3 | Completed | Systemic Lupus Erythematosus | 442 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01395745) |
| May 25, 2011 | NCT01359605 | Study to Assess the Metabolism and Elimination of \[14C\]-Labeled Varespladib Methyl in Healthy Male Subjects | Anthera Pharmaceuticals | Phase 1 | Completed | Healthy Volunteers | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01359605) |
| May 25, 2011 | NCT01359579 | A Study of the Pharmacokinetics and Safety of Varespladib in Subjects With Normal or Impaired Renal Function | Anthera Pharmaceuticals | Phase 1 | Terminated | Renal Impairment | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01359579) |
| March 1, 2011 | NCT01305746 | A Trial for Subjects With Systemic Lupus Erythematosus Who Have Completed Protocol AN-SLE3321 | Anthera Pharmaceuticals | Phase 2 | Completed | Systemic Lupus Erythematosus | 382 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01305746) |
| July 15, 2010 | NCT01162681 | PEARL-SC Trial: A Study of the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus | Anthera Pharmaceuticals | Phase 2 | Completed | Systemic Lupus Erythematosus | 547 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01162681) |
| May 25, 2010 | NCT01130246 | VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary Syndrome | Anthera Pharmaceuticals | Phase 3 | Terminated | Acute Coronary Syndrome | 5,189 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01130246) |
| August 29, 2008 | NCT00743925 | FRANCIS-ACS Trial: A Study of the Safety and Efficacy of A 002 in Subjects With Acute Coronary Syndromes | Anthera Pharmaceuticals | Phase 2 | Completed | Acute Coronary Syndrome | 625 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00743925) |
| September 6, 2007 | NCT00525954 | PLASMA 2 Trial: Examination of Once Daily (QD) Dosing of A-002 In Subjects With Stable Coronary Artery Disease | Anthera Pharmaceuticals | Phase 2 | Completed | Coronary Artery Disease | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00525954) |
| July 12, 2007 | NCT00500084 | Phase III ALTU-135 CP Safety Trial | Anthera Pharmaceuticals | Phase 3 | Terminated | Exocrine Pancreatic Insufficiency | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00500084) |
| April 3, 2007 | NCT00455546 | PLASMA Trial: A Dose-Response Study of A-002 In Subjects With Stable Coronary Artery Disease | Anthera Pharmaceuticals | Phase 2 | Completed | Coronary Artery Disease (CAD) | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00455546) |
| March 21, 2007 | NCT00449904 | Open-Label Phase III Long-Term Safety Trial of Liprotamase | Anthera Pharmaceuticals | Phase 3 | Completed | Cystic Fibrosis, Exocrine Pancreatic Insufficiency | 214 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00449904) |
| March 21, 2007 | NCT00449878 | Liprotamase Efficacy Trial in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency | Anthera Pharmaceuticals | Phase 3 | Completed | Cystic Fibrosis, Exocrine Pancreatic Insufficiency | 163 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00449878) |
| February 13, 2007 | NCT00434473 | IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome | Anthera Pharmaceuticals | Phase 2 | Completed | Sickle Cell Disease, Vaso-occlusive Crisis, Acute Chest Syndrome | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00434473) |
| November 9, 2004 | NCT00095732 | Oral TheraCLEC™ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency | Anthera Pharmaceuticals | Phase 2 | Completed | Cystic Fibrosis, Pancreatic Insufficiency | 129 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00095732) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 2 |
| Phase 2 | 9 |
| Phase 2/3 | 2 |
| Phase 3 | 11 |
| Phase 4 | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 15 |
| Terminated | 5 |
| Withdrawn | 4 |
| Unknown | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Exocrine Pancreatic Insufficiency | 8 |
| Cystic Fibrosis | 7 |
| Lupus Erythematosus, Systemic | 5 |
| Autoimmune Diseases | 5 |
| Coronary Artery Disease | 2 |
| Nephritis | 2 |
| Glomerulonephritis, IGA | 2 |
| Anemia, Sickle Cell | 2 |
| Vaso-Occlusive Crises | 2 |
| Acute Coronary Syndrome | 2 |
| Atherosclerosis | 1 |
| Granulomatosis with Polyangiitis | 1 |
| Microscopic Polyangiitis | 1 |
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 |
| Kidney Diseases | 1 |
| Angina, Unstable | 1 |
| ST Elevation Myocardial Infarction | 1 |
| Non-ST Elevated Myocardial Infarction | 1 |
| Purpura, Thrombocytopenic, Idiopathic | 1 |
| Pancreatitis, Chronic | 1 |
| Renal Insufficiency | 1 |
| Acute Chest Syndrome | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Home automation companies in the United States](https://specstream.ai/data/businesses/home-automation-companies/united-states)
- [Motels in the United States](https://specstream.ai/data/businesses/motels/united-states)
- [Rubber and plastics manufacturers in the United States](https://specstream.ai/data/businesses/rubber-and-plastics-manufacturers/united-states)
- [Web hosting companies in the United States](https://specstream.ai/data/businesses/web-hosting-companies/united-states)
- [Breakfast and brunch restaurants in the United States](https://specstream.ai/data/businesses/breakfast-and-brunch-restaurants/united-states)
